Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
单位：[1]Harbin Med Univ, Canc Hosp, Med Oncol, Harbin, Heilongjiang, Peoples R China[2]Zhejiang Univ, Affiliated Hosp 1, Med Oncol, Hangzhou, Zhejiang, Peoples R China浙江大学医学院附属第一医院[3]Tongji Hosp, Oncol, Wuhan, Hubei, Peoples R China肿瘤科华中科技大学同济医学院附属同济医院[4]Northern Jiangsu Peoples Hosp, Oncol, Yangzhou, Jiangsu, Peoples R China[5]Xi An Jiao Tong Univ, Affiliated Hosp 1, Med Oncol, Xian, Shaanxi, Peoples R China[6]BeiGene Beijing Co Ltd, Med Oncol, Beijing, Peoples R China[7]307 Hosp Chinese Peoples Liberat Army, Affiliated Hosp, Canc Ctr, Beijing, Peoples R China
第一作者单位：[1]Harbin Med Univ, Canc Hosp, Med Oncol, Harbin, Heilongjiang, Peoples R China
推荐引用方式(GB/T 7714)：
Bai Y.,Xu N.,Yuan X.,et al.Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)[J].ANNALS OF ONCOLOGY.2019,30:
APA：
Bai, Y.,Xu, N.,Yuan, X.,Wang, B.,Li, E....&Xu, J..(2019).Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC).ANNALS OF ONCOLOGY,30,
MLA：
Bai, Y.,et al."Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)".ANNALS OF ONCOLOGY 30.(2019)
医学